Galimedix, Inc. | Finanzwire

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 12/05/2024 at 13:33, 16 days 6 hours ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 16 days 6 hours ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 6 months 11 days ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 6 months 11 days ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 9 months 13 days ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 9 months 13 days ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024
BRIEF

published on 02/28/2024 at 14:00, 9 months 22 days ago

Galimedix Therapeutics Presents New Preclinical Data on GAL-201 at AD/PD™ 2024 Conference

Alzheimer's Disease GAL-201 AD/PD™ 2024 Galimedix Therapeutics Preclinical
PRESS RELEASE

published on 02/28/2024 at 14:00, 9 months 22 days ago

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference
Galimedix Therapeutics to present new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model at AD/PD™ 2024 Conference, showing promise in targeting amyloid beta oligomers and protofibrils

Alzheimer's Disease GAL-201 Galimedix Therapeutics Pre-clinical Data AD/PD™ 2024 Conference
PRESS RELEASE

published on 10/25/2023 at 14:00, 1 year 1 month ago

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

Accesswire

Published on 12/21/2024 at 01:30, 18 hours 6 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 18 hours 6 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 31 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 36 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 20 hours 6 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 45 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 51 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 7 hours 19 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days 1 hour ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE